Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17807
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJo, Helen E-
dc.contributor.authorGlaspole, Ian-
dc.contributor.authorGrainge, Christopher-
dc.contributor.authorGoh, Nicole S L-
dc.contributor.authorHopkins, Peter M A-
dc.contributor.authorMoodley, Yuben-
dc.contributor.authorReynolds, Paul N-
dc.contributor.authorChapman, Sally-
dc.contributor.authorWalters, E Haydn-
dc.contributor.authorZappala, Christopher-
dc.contributor.authorAllan, Heather-
dc.contributor.authorKeir, Gregory J-
dc.contributor.authorHayen, Andrew-
dc.contributor.authorCooper, Wendy A-
dc.contributor.authorMahar, Annabelle M-
dc.contributor.authorEllis, Samantha-
dc.contributor.authorMacansh, Sacha-
dc.contributor.authorCorte, Tamera J-
dc.date2017-02-23-
dc.date.accessioned2018-05-28T06:13:54Z-
dc.date.available2018-05-28T06:13:54Z-
dc.date.issued2017-02-
dc.identifier.citationThe European Respiratory Journal 2017; 49(2): 1601592en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17807-
dc.description.abstractThe prevalence of idiopathic pulmonary fibrosis (IPF), a fatal and progressive lung disease, is estimated at 1.25-63 out of 100 000, making large population studies difficult. Recently, the need for large longitudinal registries to study IPF has been recognised.The Australian IPF Registry (AIPFR) is a national registry collating comprehensive longitudinal data of IPF patients across Australia. We explored the characteristics of this IPF cohort and the effect of demographic and physiological parameters and specific management on mortality.Participants in the AIPFR (n=647, mean age 70.9±8.5 years, 67.7% male, median follow up 2 years, range 6 months-4.5 years) displayed a wide range of age, disease severity and co-morbidities that is not present in clinical trial cohorts. The cumulative mortality rate in year one, two, three and four was 5%, 24%, 37% and 44% respectively. Baseline lung function (forced vital capacity, diffusing capacity of the lung for carbon monoxide, composite physiological index) and GAP (gender, age, physiology) stage (hazard ratio 4.64, 95% CI 3.33-6.47, p<0.001) were strong predictors of mortality. Patients receiving anti-fibrotic medications had better survival (hazard ratio 0.56, 95% CI 0.34-0.92, p=0.022) than those not on anti-fibrotic medications, independent of underlying disease severity.The AIPFR provides important insights into the understanding of the natural history and clinical management of IPF.en_US
dc.language.isoeng-
dc.titleBaseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleThe European Respiratory Journalen_US
dc.identifier.affiliationDept of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, Australiaen_US
dc.identifier.affiliationFaculty of Medicine, University of Sydney, Sydney, Australiaen_US
dc.identifier.affiliationDept of Allergy and Respiratory Medicine, The Alfred Hospital, Melbourne, Australiaen_US
dc.identifier.affiliationFaculty of Medicine, Monash University, Melbourne, Australiaen_US
dc.identifier.affiliationDept of Respiratory Medicine, John Hunter Hospital, Newcastle, Australiaen_US
dc.identifier.affiliationRespiratory and Sleep Medicineen_US
dc.identifier.affiliationSchool of Medicine, University of Queensland, Brisbane, Australiaen_US
dc.identifier.affiliationDept of Respiratory Medicine, Fiona Stanley Hospital, Perth, Australiaen_US
dc.identifier.affiliationDept of Respiratory Medicine, Royal Adelaide Hospital, Adelaide, Australiaen_US
dc.identifier.affiliationUniversity of Tasmania, Hobart, Australiaen_US
dc.identifier.affiliationDept of Thoracic Medicine, Royal Brisbane & Women's Hospital, Brisbane, Australiaen_US
dc.identifier.affiliationLung Foundation Australia, Brisbane, Australiaen_US
dc.identifier.affiliationDept of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Australiaen_US
dc.identifier.affiliationTissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australiaen_US
dc.identifier.affiliationDept of Radiology, The Alfred Hospital, Melbourne, Australiaen_US
dc.identifier.doi10.1183/13993003.01592-2016en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-1183-2729en_US
dc.identifier.pubmedid28232409-
dc.type.austinJournal Article-
dc.type.austinMulticenter Study-
dc.type.austinObservational Study-
local.name.researcherGoh, Nicole S L
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptRespiratory and Sleep Medicine-
crisitem.author.deptInstitute for Breathing and Sleep-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

10
checked on Nov 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.